{"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}],"groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"35","upperLimit":"72","value":"57"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"Acute Myeloid Leukemia (AML)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Myelodysplastic Syndrome (MDS)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Chronic Myelomonocytic Leukemia (CMML)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Diagnosis","unitOfMeasure":"Participants"}]}